Massachusetts Weekly
SEE OTHER BRANDS

The most trusted news from Massachusetts

Massachusetts Weekly: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Weekly.

Press releases published on May 17, 2025

انتشار «میراث خیامی»: آخرین کتاب مجموعۀ ١٢-جلدى «راز عمر خیام » شامل کلّيات آثار او و فشردۀ يافته هاى مجموعه خواهد بود

انتشار «میراث خیامی»: آخرین کتاب مجموعۀ ١٢-جلدى «راز عمر خیام » شامل کلّيات آثار او و فشردۀ يافته هاى مجموعه خواهد بود

آخرین کتاب مجموعۀ ١٢-جلدى «راز عمر خیام: پيام شناسى رباعیات در انديشۀ جامعه‌شناسی ذره-موجى» شامل کلّيات آثار اوست که در منطق هزار رباعىِ حسب حالش به اوج رسيدند. GREATER BOSTON, MA, UNITED STATES, May 17, 2025 /⁨EINPresswire.com⁩/ -- آخرین کتاب مجموعۀ «راز …

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”) In new echocardiographic …

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adherence, and tolerability challenges seen with current GLP- …

Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the American Society of Gene and Cell Therapy 28th Annual Meeting

Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the American Society of Gene and Cell Therapy 28th Annual Meeting

Presented new preclinical data in non-human primates (NHP) for alpha-1 antitrypsin deficiency (AATD) and phenylketonuria (PKU), where RNA Gene Writer achieved an estimated 76% and 70% editing in hepatocytes1, respectively New AATD data reinforced the …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service